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O B J E C T I V E S To evaluate the relationship between serial cardiac troponin T (cTnT) levels with
infarct size and left ventricular ejection fraction by gated single-photon emission computed tomography
myocardial perfusion imaging (SPECT-MPI) in patients with acute myocardial infarction (AMI).
B A C KG ROUND Current guidelines recommend the use of cTnT as the biomarker of choice for the
diagnosis of AMI. Data relating cTnT to SPECT-MPI in patients with AMI are limited.
METHOD S A subset of patients with their ﬁrst AMI participating in a community-based cohort of
AMI in Olmsted County, Minnesota, were prospectively studied. Serial cTnT levels were evaluated at
presentation, 12 h and 1, 2, and 3 days after onset of pain. Peak cTnT was deﬁned as the maximum
cTnT value.
R E S U L T S A total of 121 patients (age, 61  13 years; 31% women) with AMI underwent gated
SPECT-MPI at a median (25th percentile, 75th percentile) of 10 (5, 15) days post-AMI. The type of infarct
was non–ST-segment elevation myocardial infarction in 61%, and 13% were anterior in location. The
median infarct size was 1% (0%, 11%) and the median gated left ventricular ejection fraction was 54%
(47%, 60%). Fifty-nine patients (49% of the population) had no measurable infarction by SPECT-MPI.
Independent predictors of measurable SPECT-MPI infarct size included cTnT at days 1, 2, and 3 and peak
cTnT, but not at presentation or 12 h. In receiver-operator characteristic analysis, the area under the
curve was highest at day 3. Receiver-operator characteristic analysis demonstrated a cutoff of 1.5 ng/ml
for peak cTnT for the detection of measurable infarct size.
CONC L U S I O N S In a community-based cohort of patients with their ﬁrst AMI, independent
predictors of measurable SPECT-MPI infarct size included cTnT at days 1, 2, and 3 and peak cTnT. In
contrast, cTnT level at presentation and 12 h was not an independent predictor of myocardial
infarction size as assessed by SPECT-MPI. Receiver-operator characteristic analysis demonstrated a cutoff
value peak cTnT of 1.5 ng/ml for the detection of measurable infarct. (J Am Coll Cardiol Img 2011;4:
523–33) © 2011 by the American College of Cardiology Foundation
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524T
he American College of Cardiology/
European Society of Cardiology diagnostic
criteria for acute myocardial infarction (AMI)
combine ischemic symptoms and/or electro-
cardiographic changes with biochemical markers of
myocardial necrosis (1). Cardiac troponin (cTn) has
been designated as the biomarker of choice for the
diagnosis of AMI (1). Serial cTn samples should
See page 534
be acquired at presentation and 6 to 9 h in most
patients, with a third sample at 12 to 24 h in the
occasional patient in whom the initial measure-
ments are not elevated and the clinical index of
suspicion remains high (1,2).
Current clinical practice in the United
States involves serial cTn measurements dur-
ing the initial hours after presentation. In the
setting of AMI, cardiac troponin T (cTnT)
appears in the serum within 1 to 3 h and
remains elevated for 4 to 10 days (1). An
elevated cTn value establishes the diagnosis of
infarction (1), but the clinical significance of
the magnitude of elevation of cTn is not clear.
Clinicians commonly assume that cTn values
measured at presentation and at 6 to 9 h later
reflect infarct size. However, only a small
number of studies have examined the associa-
tion between cTn values and infarct size with
variable results (3–7). The optimal time to
sample cTn that best predicts infarct size is
unknown. Nonetheless, cTn release as a reflec-
tion of infarct size is already being used as an
endpoint to assess the efficacy of therapy in
AMI trials (8).
Infarct size can be accurately quantitated by
both the size of the perfusion defect on single-
hoton emission computed tomography myocardial per-
usion imaging (SPECT-MPI) and left ventricular ejec-
ion fraction (LVEF) (9). Infarct size measured by
PECT-MPI (10–12) or LVEF (12,13) is a powerful
redictor of outcome post-AMI. Accordingly, the aim of
his study was to evaluate the associations between serial
alues of cTnT and nuclear indices of infarct size in a
eries of patients with their first AMI, diagnosed with
he American College of Cardiology/European Society
f Cardiology criteria (1).
M E T H O D S
Patients. The study was approved by the Mayo
ion
ion
y
ssion
phy
glinic Institutional Review Board. Patients pro- aided written informed consent. We prospectively
ecruited a sample of 121 patients hospitalized with
heir first AMI between November 2002 and Oc-
ober 2007. These patients represented a subset of
atients who were enrolled in a prospective,
ommunity-based AMI study from Olmsted
ounty, Minnesota, designed to examine changes
n the incidence of AMI diagnosis resulting from
sing cTnT in place of the myocardial bound
raction of creatine kinase (CK-MB). Details of this
tudy have been published elsewhere (14). For
yocardial infarction diagnosis, we applied a com-
uterized algorithm that integrated ischemic symp-
oms, the Minnesota code of the electrocardio-
rams, and cTnT levels (14). For this algorithm, 3
lectrocardiograms were electronically available and
ere coded using a previously validated electronic
oding system. For those patients who were trans-
erred from another medical facility in Olmsted
ounty to the Mayo Clinic Emergency Depart-
ent (n  13), the presentation electrocardiograms
ere not electronically available. For these trans-
erred patients, the clinician’s interpretation of the
lectrocardiogram recorded in the medical record
as used for the AMI diagnosis.
Because nuclear indices of infarction cannot sep-
rate a past from a current AMI, only patients with
documented first AMI were enrolled in this
ubstudy. The linkage system from the Rochester
pidemiology Project (15) enabled the identifica-
ion of patients with a previous AMI by history.
lectrocardiograms and electronic medical records
f all eligible patients were reviewed to exclude
atients with significant Q waves on the electrocar-
iograms or evidence of reduced LVEF, regional
all motion abnormalities, or perfusion defect on
ny previous cardiac imaging modality (e.g., echo-
ardiography, SPECT-MPI). Because periproce-
ural AMI can be difficult to diagnose, patients
ith a history of percutaneous coronary interven-
ion (PCI) or coronary artery bypass surgery were
ot included in this study. There were 37 patients
ot included in this study because of a history of
yocardial infarction or revascularization, and 78
atients declined to participate in this study.
Clinical data obtained included comorbidities
easured by the Charlson index (16) and Killip
lass. Clinical diagnoses were used to ascertain
ypertension, diabetes mellitus, hyperlipidemia,
amily history of coronary disease, and smoking
tatus. Medications recorded during the hospital-
zation for the acute event included beta-blockers,A B B R E V I A T I O N S
A N D A C R O N YM S
AMI acute myocardial
infarction
CK-MBmyocardial bound
fraction of creatine kinase
cTn cardiac troponin
cTnT cardiac troponin T
VEF left ventricular eject
raction
STEMI non–ST-segment
elevation myocardial infarct
PCI percutaneous coronar
intervention
ROC receiver-operator
characteristic
SPECT single-photon emi
computed tomography
SPECT-MPI single-photon
emission computed tomogra
myocardial perfusion imaginngiotensin-converting enzyme inhibitors, angio-
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525tensin II receptor blockers, statins, and aspirin.
Reperfusion or revascularization therapy was de-
fined as the use of thrombolytic therapy, PCI, or
coronary artery bypass surgery during the same
hospitalization. All decisions regarding patient
management were left to the discretion of the
attending cardiologists, the vast majority of whom
were not investigators in this study.
Serial cTnT. All patients had an increase in cTnT
evel of 0.03 ng/ml (14). This threshold was the
0% coefficient variation for the assay used at our
nstitution during the time frame of this study.
TnT was measured by the third-generation cTnT
ssay (17) in the Department of Laboratory Med-
cine and Pathology, which is certified by the
linical Laboratory Improvement Act of 1988 and
y the College of American Pathologists.
Levels of cTnT were ordered at the discretion of
he attending cardiologists. For this reason, cTnT
evels were not available at all time points in all
atients. Serial cTnT levels were obtained at pre-
entation (n 121),12 h (n 96), 12 to 24 h (99
patients), day 2 (n  72), and day 3 (n  45). We
performed a preliminary analysis of our data after
the evaluation of 53 patients and recognized the
potential value of obtaining later measurements of
cTnT at 4 days. From this time point forward,
cTnT values were obtained at 4 days when
possible but in only 29 patients, and those samples
were not included in this analysis due to the small
number.
Technetium-99m sestamibi SPECT-MPI. All patients
nderwent gated SPECT-MPI at a median of 10
ays (25th percentile, 75 percentile: 5 days, 15 days)
ost-AMI. For this study, 45 patients underwent a
linically indicated stress SPECT-MPI, and 76
atients underwent a research SPECT-MPI if not
rdered for clinical reasons. All imaging was per-
ormed at least 117 h after the onset of symptoms.
his time frame was selected because SPECT-MPI
erformed before the fifth day has been shown to
verestimate infarct size. For the clinically indicated
tress tests (1 day rest-stress sequence), 8 to 12 mCi
f technetium-99m (Tc-99m) sestamibi was ad-
inistered for the resting images and 32 to 48 mCi
f Tc-99m sestamibi for the stress images. For the
esearch scans, patients underwent resting imaging
nly and received an intravenous injection of 20 to
0 mCi of Tc-99m sestamibi. Infarct size was
etermined from the resting images. LVEF was
alculated from the post-stress gated images.
SPECT images were acquired beginning 45 to
0 min after the Tc-99m sestamibi injection using drotating gamma camera with a low-energy, all-
urpose collimator. Processing and reconstruction
ere performed using standard back-projection al-
orithms and a Ramp-Hanning filter. Infarct size
as quantitated using established methods (10).
ircumferential count profiles were generated for 5
epresentative short-axis slices of the left ventricle
xtending from apex to base. Infarct size was
uantitated using a threshold value of 60% of peak
ounts. The defect size was expressed as a percent-
ge of the left ventricle. Gated SPECT LVEF was
easured using QGS software (Cedars-Sinai Med-
cal Center, Los Angeles, California) (18). LVEF
as not available in 22 patients (18%) due to
echnical factors.
Coronary angiography. Coronary angiography was
performed at the discretion of the attending cardi-
ologist. The angiograms were interpreted by 2
experienced observers according to the CASS (Cor-
onary Artery Surgery Study) coding system: 50
left main stenosis or 70% stenosis of the left
anterior descending, left circumflex, or right coro-
nary arteries or their major branches considered
significant (19). The success of PCI was determined
by the same individuals.
Follow-up. Follow-up data were obtained at a mean
duration of 4.8  1.6 years. Data were obtained by
surveillance of medical records. The ascertainment
of death incorporated death certificates filed in
Olmsted County, autopsy reports, obituary notices,
and electronic files of death certificates obtained
from the State of Minnesota Department of Vital
and Health Statistics (15). The diagnosis of heart
failure was validated using the Framingham criteria
(20). We previously reported the reliability of the
application of these diagnostic criteria in our cohort
(21). Major cardiac events at follow-up were de-
fined as death or heart failure.
Statistical analysis. Data are presented as frequencies
or categorical variables, as mean  SD for contin-
ous variables, or as medians with 25th and 75th
ercentiles for variables with skewed distribution.
ime zero was defined as the time of onset of
ymptoms. cTnT values were categorized using the
ollowing approach: 12 h; 12 to 24 h, day 2, day
, and peak. A value was defined as peak if it was
he highest in the time course. In a secondary
nalysis, models were repeated considering time
ero as the time of presentation to the emergency
epartment. For the secondary analysis, we also
ategorized the time points as 12 h; 12 to 24 h,
ay 2, day 3, and peak.
m
e
e
A
t
A
t
u
s
f
p
a
f
a
e
c
v
w
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 5 , 2 0 1 1
M A Y 2 0 1 1 : 5 2 3 – 3 3
Arruda-Olson et al.
SPECT and Troponin
526Unadjusted and adjusted logistic regression mod-
els were developed to test the associations of mea-
surements of cTnT at each of these time points
with SPECT-MPI infarct size of 0% (nonmeasur-
able infarct) or 1% (measurable infarct). The
odels were adjusted for age, sex, ST-segment
levation myocardial infarction or non–ST-
levation myocardial infarction (NSTEMI), and
MI location. These variables were chosen from
hose known to be of clinical relevance for post-
MI risk stratification.
Receiver-operator characteristic (ROC) curves
were analyzed to evaluate the relationship between
cTnT values at the time points and measurable and
nonmeasurable SPECT-MPI infarct size. Using
ROC analysis, the best cutoff of cTnT for the
detection of measurable SPECT-MPI infarct size
at each time point was identified.
The correlations between cTnT and SPECT-
MPI infarct size and between cTnT and LVEF
were analyzed by the Spearman test. The Spearman
test was also used to analyze the correlation between
infarct size and peak cTnT in patients who under-
went PCI 9 h versus 9 h from onset of symp-
oms to first balloon inflation. This time point was
sed because 9 h was the median time from onset of
ymptoms to first balloon inflation. There were too
ew patients to evaluate this issue at multiple time
oints including very early (within 2 h).
Unadjusted and adjusted Cox proportional haz-
rd regression models were constructed using in-
arct size or peak cTnT to estimate hazard ratios
nd 95% confidence intervals for major cardiac
vents. For all analyses, a p value 0.05 was
onsidered statistically significant. SAS software
ersion 9.1 (SAS Institute, Cary, North Carolina)
as used for all statistical analyses.
R E S U L T S
Clinical characteristics. The mean age of the popu-
lation was 61  13 years, and approximately two-
thirds were men. The study cohort was generally a
low-risk AMI population: 84% of patients were
Killip class I or II, and most (86%) had a low
Charlson comorbidity index. The type of infarct
was NSTEMI in 61%, and 13% were anterior in
location (Table 1).
Patients who had cTnT levels measured at day 2 and
later (n  28) were more likely to have a diagnosis of
NSTEMI and more likely to undergo PCI later during
hospitalization (median, 38 h; 25th percentile, 75th
percentile: 25 h, 53 h) than patients who did not havecTnT levels measured at day 2 and later (median, 11 h;
25th percentile, 75th percentile: 4 h, 27 h) (p 0.003).
All other clinical, biochemical, and angiographic charac-
Table 1. Baseline Clinical Characteristics
Age, yrs 61 13
Men 84 (69)
Killip class
I 98 (81)
II 4 (3)
III 18 (15)
IV 1 (1)
Comorbidity index
0 58 (48)
1–2 46 (38)
3 17 (14)
Electrocardiogram
NSTEMI 74 (61)
Infarct location
Anterior 16 (13)
Inferior 24 (20)
Lateral 8 (7)
Combined 29 (24)
Indeterminate 44 (36)
cTnT, ng/ml
Presentation (n  121) 0.04 (0.01, 0.16)
12 h (n  96) 0.40 (0.14, 3.31)
Day 1 (n  99) 0.90 (0.25, 3.01)
Day 2 (n  72) 1.08 (0.18, 1.92)
Day 3 (n  45) 1.20 (0.17, 3.08)
Peak (n  121) 1.46 (0.35, 4.10)
Medications
Beta-blockers 111 (97)
ACE/ARBs 88 (77)
Statins 96 (83)
Aspirin 114 (99)
Risk factors
Hypertension 66 (54)
Hyperlipidemia 72 (59)
Diabetes mellitus 21 (17)
Family history of CAD 22 (18)
Current smoker 32 (26)
Reperfusion 93 (77)
Percutaneous coronary intervention 90 (74)*
Coronary artery bypass surgery 2 (2)
Thrombolysis 1 (1)
Coronary angiography 104†
0-vessel CAD 5
1-vessel CAD 46
2-vessel CAD 37
3-vessel CAD 16
Left main CAD 1
Continued on next pageteristics were similar in these 2 groups of patients.
w
d
I
h
p
t
(
t
s
1
m
e
s
p
A
L
t
t
w
p
7
w
2
n
m
w
e
p
s
a
d
s
c
w
R
a
c
o
m
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 5 , 2 0 1 1
M A Y 2 0 1 1 : 5 2 3 – 3 3
Arruda-Olson et al.
SPECT and Troponin
527Seventy-seven percent of patients were treated
with reperfusion therapy, most of whom underwent
PCI (Table 1). Patients who did not undergo
reperfusion (n  28) were older (68  14 years vs.
59  13 years; p  0.002), were more likely to be
omen (61% vs. 21%, p  0.001, and have a
iagnosis of NSTEMI (89% vs. 53%, p  0.001).
n addition, those who did not undergo reperfusion
ad lower peak cTnT (median, 0.4 ng/ml; 25th
ercentile, 75th percentile: 0.1 ng/ml, 1.5 ng/ml)
han those who underwent reperfusion therapy
median, 1.8 ng/ml; 25th percentile, 75th percen-
ile: 0.6 ng/ml, 4.7 ng/ml; p  0.001).
SPECT-MPI infarct size and LVEF. The median infarct
ize was 1% (25th percentile, 75th percentile: 0%,
Table 1. Continued
Infarct-related coronary artery
LAD 71
LCX 40
RCA 53
No. of stents 1.2 0.7
Successful PCI (20% stenosis) 83 (92)
Percentage of stenosis‡
Before PCI, median (25th, 75th percentiles) 99 (90, 100)
After PCI, median (25th, 75th percentiles) 0 (0, 0)
Values are mean  SD, n (%), median (25th percentile, 75th percentile), or n.
*Five PCIs were percutaneous transluminal coronary angioplasty only. †Total
number of patients who underwent coronary angiography during the same
episode of care. ‡p  0.001 for comparison of percentage of stenosis before
and after PCI.
ACE/ARB  angiotensin-converting enzyme/angiotensin II receptor blocker;
CAD coronary artery disease; cTnT cardiac troponin T; LAD left anterior
descending artery; LCX  left circumﬂex artery; NSTEMI  non–ST-segment
elevation myocardial infarction; PCI  percutaneous coronary intervention;
RCA  right coronary artery.
20
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Figure 1. Distribution of SPECT-MPI Infarct Size and LVEF
Almost one-half of patients had no measurable infarct size (A). Mos
LV  left ventricle; SPECT-MPI  single-photon emission computed tom1%). Almost one-half (49%) of patients had no
easurable infarct size (Fig. 1). Figure 2 shows an
xample of no measurable infarct size and Figure 3
hows a measurable infarct size. Only 25% of
atients had infarct size 10% of the left ventricle.
mong the 99 patients who had a measurable
VEF, the median LVEF was 54% (25th percen-
ile, 47%; 75th percentile, 60%). Of those, nearly
wo-thirds (62%) had an LVEF 50%. Patients
ith a measurable infarct size had higher values for
eak cTnT (median, 2.9 ng/ml; 25th percentile,
5th percentile: 0.9 ng/ml, 6.2 ng/ml) than those
ithout a measurable infarct (median, 0.7 ng/ml;
5th percentile, 75th percentile: 0.2 ng/ml, 1.8
g/ml; p  0.0001).
Relationship between cTnT with SPECT-MPI infarct size
and LVEF. In the unadjusted logistic regression
odel, admission cTnT level was not associated
ith measurable SPECT-MPI infarct size. How-
ver, cTnT values at 12 h, days 1, 2, and 3, and
eak were all associated with the presence of mea-
urable infarct size (Table 2). After adjusting for
ge, sex, and type and location of AMI, indepen-
ent predictors of measurable SPECT-MPI infarct
ize included cTnT at days 1, 2, and 3 and peak
TnT; cTnT at 12 h was no longer associated
ith measurable SPECT-MPI infarct size. In
OC analysis, the area under the curve was highest
t day 3 (Fig. 4). ROC analysis demonstrated a
utoff of 1.5 ng/ml for peak cTnT for the detection
f measurable infarct size (Fig. 4).
There were significant positive correlations of the
agnitude of cTnT values at days 1, 2, and 3 and
20
40
60
LVEF (%)
n = 99
B
0
<40 40-50 >50
tients had preserved left ventricular ejection fraction (LVEF) (B).t pa
ography myocardial perfusion imaging.
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528peak with infarct size, but r values were modest
(Fig. 5). Of note, SPECT-MPI did not detect
infarction in 49% of patients who met the cTnT
threshold for infarction. There were significant
negative correlations of LVEF and cTnT values at
days 1, 2, and 3 and peak cTnT also with modest r
values (Fig. 6). There were similar correlations
between infarct size and peak cTnT in those pa-
tients 9 h from onset of symptoms to first balloon
inflation (r  0.47, p  0.001) versus those 9 h
from onset of symptoms to first balloon inflation
(r  0.48, p  0.001).
In a secondary analysis considering time zero as
the time of presentation, cTnT level 12 h was
associated with SPECT-MPI infarct size in the
unadjusted logistic model (odds ratio: 1.22, p 
0.009). This association persisted after adjustment
(odds ratio: 1.23, p  0.03). For all other time
points, the associations were similar to the associ-
ations described that used time zero as the onset of
symptoms.
Follow-up. During follow-up, 10 patients died and
Figure 2. Example of Nonmeasurable Infarct Size
Stress and rest images of an 80-year-old man who presented 2 h a
myocardial infarction. Initial cardiac troponin T (cTnT) was 0.21 ng/m
tomography myocardial perfusion imaging showed no perfusion de
long axis; SA  short axis; VLA  vertical long axis.15 experienced heart failure. Both infarct size (haz-ard ratio: 1.4; 95% confidence interval: 1.1 to 14.2;
p  0.006) and peak cTnT (hazard ratio: 2.8; 95%
confidence interval: 1.1 to 6.9; p  0.03) were
significantly associated with major cardiac events.
The association between infarct size and major
cardiac events persisted after adjustment for age
(p  0.003) and sex (p  0.006). The association
between peak cTnT and major cardiac events also
persisted after adjustment for age (p  0.003) and
sex (p  0.03).
D I S C U S S I O N
In this community-based cohort of patients with
their first AMI defined by contemporary criteria,
novel findings include that SPECT-MPI did not
detect measurable infarct in nearly half of the
patients and that independent predictors of mea-
surable SPECT-MPI infarct size were cTnT levels
at days 1, 2, and 3 and peak. In addition, ROC
analysis demonstrated a peak cTnT cutoff value of
onset chest pain with an anterior wall non–ST-segment elevation
TnT at day 3 was 1.8 ng/ml. Single-photon emission computed
s. Left ventricular ejection fraction was 55%. HLA  horizontalfter
l. c
fect1.5 ng/ml for the detection of measurable infarct.
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529Finally, infarct size and peak cTnT were associated
with major cardiac events at follow-up.
cTnT and SPECT for the diagnosis of AMI. In a previ-
ous study (14), we reported that implementation of
cTnT in place of CK-MB for the diagnosis of AMI
resulted in a 74% increase in the number of AMIs
with a change in the case mix. Patients with a
diagnosis of AMI by cTnT criteria only were less
likely to have ST-segment elevation myocardial
infarction and had better survival compared with
Figure 3. Example of Measurable Infarct Size
Rest-only images of a 47-year-old-man who presented 21 h after th
myocardial infarction treated with direct percutaneous coronary int
day 3 was 7.7 ng/ml. Single-photon emission computed tomograph
anterolateral, and anteroseptal perfusion defect. Infarct size was qu
was 32%. CI  conﬁdence interval; other abbreviations as in Figure
Table 2. Associations Between cTnT and Measurable
SPECT-MPI Infarct Size
Time
Odds Ratio (p Value)
Unadjusted Adjusted*
Presentation 1.00 (0.98) 0.97 (0.86)
12 h 1.17 (0.04) 1.18 (0.10)
Day 1 1.27 (0.01) 1.26 (0.03)
Day 2 1.78 (0.007) 1.66 (0.02)
Day 3 2.03 (0.007) 2.27 (0.008)
Peak 1.33 (0.001) 1.34 (0.003)
*Adjusted for age, sex, acute myocardial infarction type, and location; odds
ratios are expressed per every 1-ng/ml increase in cTnT.
cTnT  cardiac troponin T; SPECT-MPI  single-photon emission computedrtomography myocardial perfusion imaging.those diagnosed by the traditional CK-MB ap-
proach (14). These changes resulted from the in-
creased sensitivity of cTnT versus CK-MB, pre-
sumably resulting in the identification of patients
with smaller infarcts. The results of the present
imaging study support this concept. In this study,
61% of patients had NSTEMI; furthermore, ap-
proximately 50% of patients had no measurable
infarct by SPECT-MPI and another 25% had an
infarct size between 1% and 10% of the left ventri-
cle. SPECT-MPI can detect infarcts as small as 3%
of the left ventricle (22) but can miss smaller
infarcts, especially nontransmural infarcts involving
50% of the left ventricular wall thickness, as
demonstrated by studies using cardiac magnetic
resonance (23).
Troponin and infarct size. The peak level of CK-
B, the former biomarker for establishing the
iagnosis of AMI, was shown to reflect infarct size
nd was accepted as a clinical method for estimating
nfarct size (9,24). This measurement is less reliable
n patients treated with reperfusion therapy (9).
lthough an elevated troponin level is currently
set of chest pain with an anterior wall ST-segment elevation
ntion. Initial cardiac troponin T (cTnT) was 4.55 ng/ml. cTnT at
yocardial perfusion imaging showed a large anterior, apical,
tated at 55% of the left ventricle. Left ventricular ejection fractione on
erve
y m
antiequired for diagnostic purposes (1,2), there are few
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530data examining the optimal timing intervals for
obtaining cTn samples or the magnitude of cTn
levels for determining infarct size.
In a previous study of 61 patients with AMI (31
ST-segment elevation myocardial infarctions and
30 NSTEMIs) who underwent serial cTnT assay
and cardiac magnetic resonance for infarct size,
measurements of cTnT within 4 days after the acute
event correlated with infarct size except for the
admission cTnT (4). In our study, we confirmed
these observations in a larger sample size, using a
different imaging modality. We observed that cTnT
levels measured after the first 24 h post acute event
are associated with SPECT-MPI indices of in-
farct size. The previous study (4) also reported
ignificant but modest correlations (r values of
.64 to 0.66 for all patients with available cTnT
evels between days 1 and 4 and cardiac magnetic
esonance infarct mass), with substantially worse
values (r  0.36 at day 4) for patients with
STEMI or those with a small infarct mass (r 
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Figure 4. ROC Analysis Displaying the Performance of cTnT to I
The area under the curve was highest at day 3. Receiver-operator c
peak cardiac troponin T (cTnT) for the detection of measurable infa
myocardial perfusion imaging..2 at day 4). In the present study, the majority ofpatients had NSTEMI or small infarct size,
helping to explain the modest r values.
A previous study reported a significant correla-
tion between single time point measurements of
cTnT at day 3 post-AMI with infarct size by
SPECT-MPI (25). A single measurement of cTnT
at day 4 post-AMI was also previously associated
with infarct size quantitated by cardiac magnetic
resonance (3). In the present study, the correlations
between cTnT and infarct size improved as the
timing post-AMI increased. However, the subset of
patients who had cTnT levels measured at day 2
and later were more likely to receive a diagnosis of
NSTEMIs and more likely to undergo reperfusion
therapy later during hospitalization. Thus, type of
AMI and more prolonged interval for reperfusion
therapy in this group of patients may have contrib-
uted to the slightly higher correlation of cTnT level
with infarct size at later time points (days 2 and 3)
observed in our present study.
Prognosis. In the present study, both infarct size
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531events at follow-up, also supporting the findings of
previous studies. Patients with “microinfarcts” di-
agnosed by cTnT criteria have a favorable prognosis
(14,26). Several studies that enrolled primarily pa-
tients with STEMI treated with reperfusion ther-
apy reported that patients with SPECT-MPI in-
farct size 10% of the left ventricle have mortality
r = 0.35
P< 0.001
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Figure 5. Correlations Between SPECT-MPI Infarct Size and Trop
There were signiﬁcant positive correlations of the magnitude of car
but r values were modest. SPECT-MPI  single-photon emission co
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Figure 6. Correlations Between LVEF and cTnT
There were signiﬁcant negative correlations between left ventricula
1, 2, and 3 and peak cTnT, also with modest r values.rates between 0% and 1% during follow-up of 6
months to 2 years (10–12,27,28).
Study limitations. Limitations of this study include
he relatively small numbers of cTnT measure-
ents, particularly the later measurements. Enroll-
ent in this study was slower than anticipated and
elated to the method of screening patients for
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532enrollment (cardiovascular research nurses carefully
reviewed each potential participant’s electronic re-
cord and excluded participants with any possible
evidence of a previous myocardial infarction on the
basis of history, electrocardiography, or imaging
study). Also, in the current era of short hospital
stay, several patients were unwilling to return for a
SPECT study for research purposes 5 days or later
after their AMI. Infarct size was quantitated by
low-dose Tc-99m sestamibi (8 to 12 mCi) resting
images in 45 patients who underwent stress
SPECT-MPI. The validation studies of previous
applications of this technique were performed in
studies in which the resting dose of Tc-99m sesta-
mibi doses was 20 to 30 mCi. Previous work
demonstrated that soft-tissue artifact could influ-
ence infarct size measurement in some obese pa-
tients (10). This issue could potentially play a more
important role in this study, given the small median
infarct size and the low-dose isotope injection for
some of the resting scans. Use of a lower dose
increases the “noise” of the images and the possi-
bility that soft-tissue attenuation is incorrectly
quantified as infarction.
Study implications. The American College of Car-and cTnI measurements in patients
1
sestamibi imaginguideline recommends obtaining cTn samples at
resentation and again 6 to 9 h later in patients with
uspected AMI. Clinicians commonly view the
agnitude of cTnT levels measured at these early
ime points as indicative of infarct size. The data
rom the present study indicate that these early
easurements of cTnT do not accurately reflect
PECT-MPI infarct size or LVEF, whereas cTnT
alues after the first 24 h are associated with indices
f infarct size. In addition, ROC analysis demon-
trated a cutoff value peak cTnT of 1.5 ng/ml for
he detection of measurable infarct. Both infarct
ize and peak cTnT identified patients at increased
isk of major cardiac events at follow-up.
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